Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies how well cytokine-treated veto cells work in treating patients
with hematologic malignancies following stem cell transplant. Giving chemotherapy and
total-body irradiation before a stem cell transplant helps stop the growth of cells in the
bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the
healthy stem cells from a donor are infused into the patient, they may help the patient's
bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Cytokine-treated veto cells may help the transplanted donor cells to develop and grow in
recipients without causing graft-versus-host-disease (GVHD - when transplanted donor tissue
attacks the tissues of the recipient's body).